Ocular Therapeutix, Inc.
Price Action
Technical Summary
CONSOLIDATINGOcular Therapeutix, Inc. is in a consolidation phase, trading with mixed signals as moving averages converge. Relative strength is weak (RS Rating: 37), showing significant lag compared to the market leaders. Earnings contraction of 5% provides fundamental context to the price action. Investors should exercise caution due to high volatility (70% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $8.79 | +13.40% | ABOVE |
| 50 SMA | $9.04 | +10.35% | ABOVE |
| 100 SMA | $8.95 | +11.45% | ABOVE |
| 150 SMA | $10.04 | -0.72% | BELOW |
| 200 SMA | $10.50 | -5.04% | BELOW |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is OCUL in an uptrend right now?
OCUL has a trend score of 2/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 2 of 4 trend criteria are met.
Is OCUL overbought or oversold?
OCUL's RSI (14) is 59. The stock is in neutral territory, neither overbought nor oversold.
Is OCUL outperforming the market?
OCUL has a Relative Strength (RS) Rating of 37 out of 99. OCUL is currently lagging the broader market.
Where is OCUL in its 52-week range?
OCUL is trading at $9.97, which is 61% of its 52-week high ($16.44) and 37% above its 52-week low ($6.23).
How volatile is OCUL?
OCUL has a Beta of 1.10 and 52-week volatility of 70%. It's more volatile than the S&P 500 - expect bigger swings.